Use of probiotics in HIV-positive individuals

• Autor(a) principal: Felipe Borges, Arissa
• Data de Publicação: 2020
• Outros Autores: Roriz Ferreira de Abreu, Vanessa
• Tipo de documento: Artigo
• Idioma: por
• Título da fonte: HU Revista (Online)
• Texto Completo: https://periodicos.ufjf.br/index.php/hurevista/article/view/28233
• topic: HIV; Acquired Immune Deficiency Syndrome; Probiotic; HIV; Síndrome da Imunodeficiência Adquirida; Probióticos

Introduction: The human immunodeficiency virus (HIV), which progressively reduces the effectiveness of the immune system, increases the susceptibility to opportunistic infections. In addition, it increases intestinal permeability and microbial translocation, which contribute to systemic immune activation, characterizing the evolution to Acquired Immunodeficiency Syndrome (AIDS). Immunological modulation of the gastrointestinal barrier in HIV with the use of probiotics has beneficial effects on host microbial balance. Objective: The present study aimed to gather data from the clinical studies literature regarding the use of probiotics in HIV-infected patients using or not antiretroviral therapy. Material and Methods: A review of the scientific literature was performed through PUBMED using the following descriptors in Health Sciences (DeCS), either alone or in combination: “human immunodeficiency virus”, “HIV”, “probiotics”. We selected studies from randomized controlled trials that involved addressing the use of probiotics in HIV-infected patients. Eleven articles with content that contributed to the fulfillment of the objectives of this study were selected. The articles were included in the English language, published in 2014 and 2018. Results: In addition to the different characteristics of the patients selected in the studies, different probiotics were tested. Interactions with immune receptors and intestinal microbiota have not yet been fully defined and may have different effects on intestinal regulation and systemic immunity. Conclusions: Understanding the interaction between the intestinal microbiome and its products in adjusting immunity in the HIV + individual will allow us to define new interventions that may decrease inflammation and disease-associated comorbidities.